Achalasia

When Swallowing Becomes Difficult: Understanding the Decision to Treat Achalasia

Achalasia can be a frightening and exhausting condition because it affects one of the most basic functions of daily life: swallowing. Many people describe a slow progression from occasional trouble with solid foods to difficulty with liquids, regurgitation of undigested food, chest discomfort, coughing at night, or unintended weight loss. Meals may become stressful. Social eating may be avoided. Some patients begin sleeping upright to reduce nighttime regurgitation or worry that their symptoms could be related to cancer, heart disease, or another serious illness.

For international patients researching treatment abroad, the questions are often very practical as well as emotional. Is the diagnosis correct? Which treatment is best: endoscopic dilation, POEM, botulinum toxin injection, or surgery? How long will recovery take? Will swallowing improve? Is reflux likely afterward? Can the full evaluation and treatment be coordinated within one trip?

Achalasia is not simply “difficulty swallowing.” It is a specific esophageal motility disorder in which the lower esophageal sphincter, the muscular valve between the esophagus and stomach, does not relax properly, and the esophageal body loses its normal coordinated squeezing motion. Food and liquids can become trapped in the esophagus instead of moving smoothly into the stomach. Over time, this can lead to worsening symptoms, nutritional problems, aspiration, and enlargement of the esophagus.

Treatment matters because achalasia usually does not resolve on its own. Modern care focuses on confirming the diagnosis accurately, understanding the type and severity of the motility disorder, and selecting a treatment that relieves obstruction at the lower esophageal sphincter. At Acibadem, patients are assessed through a coordinated pathway that may involve gastroenterologists, advanced endoscopists, gastrointestinal surgeons, radiologists, anesthesiology teams, dietitians, and, when needed, other specialists. The goal is to reduce swallowing difficulty, improve quality of life, and help patients return to eating with greater comfort and confidence.

What Achalasia Treatment Is

Achalasia treatment is a group of procedures designed to help food and liquid pass from the esophagus into the stomach more easily. Because the underlying problem is failure of the lower esophageal sphincter to relax properly, treatment is directed at reducing the pressure of this sphincter. This can be done endoscopically, surgically, or with injection therapy, depending on the patient’s diagnosis, anatomy, health status, and preferences.

The main treatment options include pneumatic dilation, peroral endoscopic myotomy, often called POEM, laparoscopic Heller myotomy, and botulinum toxin injection. Each has a different role. Pneumatic dilation uses a special balloon to stretch and disrupt the tight sphincter muscle. POEM is an advanced endoscopic procedure in which the physician creates a tunnel within the esophageal wall and cuts the tight muscle from inside. Laparoscopic Heller myotomy is a minimally invasive surgical procedure that divides the lower esophageal sphincter muscle, usually combined with an anti-reflux procedure. Botulinum toxin injection temporarily relaxes the sphincter and may be appropriate for selected patients who are not good candidates for more definitive procedures.

Medications have a limited role in achalasia. Some drugs can lower sphincter pressure for a short time, but they are generally less effective than procedural treatment and may cause side effects. For most patients with significant symptoms, durable improvement usually requires an intervention that directly addresses the lower esophageal sphincter.

The right treatment is not the same for every patient. Achalasia has different subtypes, and treatment planning often depends on high-resolution manometry findings, the patient’s age and general health, prior procedures, the degree of esophageal dilation, reflux risk, and whether other esophageal conditions are present. A patient who has early type II achalasia may be approached differently from someone with a markedly dilated esophagus, prior failed dilation, or complex spastic symptoms. A careful diagnostic pathway is therefore essential before deciding on treatment.

Who May Need Achalasia Treatment

Patients may need achalasia treatment when swallowing difficulty is persistent, progressive, or associated with regurgitation, weight loss, chest pain, recurrent respiratory symptoms, or reduced quality of life. Achalasia can occur at different ages, although it is most often diagnosed in adults. Because early symptoms may mimic acid reflux, anxiety-related swallowing difficulty, esophageal spasm, or structural narrowing, diagnosis may be delayed unless specialized testing is performed.

The most common symptom is dysphagia, meaning difficulty swallowing. In achalasia, dysphagia often affects both solids and liquids, although the pattern can vary. Patients may feel food stopping behind the breastbone, need to drink large amounts of water to move food down, or use certain body positions to help swallowing. Regurgitation is also common, especially when lying down. Unlike vomiting, regurgitation in achalasia often brings up undigested food or fluid without nausea because material has remained in the esophagus.

Other symptoms may include chest pressure, heartburn-like burning, chronic cough, hoarseness, bad breath, hiccups, or repeated chest infections caused by aspiration. Some patients lose weight because eating becomes slow, uncomfortable, or unpredictable. Others adapt so gradually that they do not realize how much their diet has narrowed until they are evaluated.

Diagnosis begins with a detailed history and physical examination, but confirmation requires testing. An upper endoscopy is commonly performed to inspect the esophagus and stomach, exclude cancer or mechanical blockage, assess retained food or fluid, and look for inflammation or other disease. A barium swallow study can show how contrast moves through the esophagus and may reveal a narrowed lower sphincter area, a dilated esophagus, or delayed emptying. The key diagnostic test is usually high-resolution esophageal manometry, which measures pressure patterns during swallowing and classifies the achalasia subtype.

In some cases, additional tests may be used, such as pH monitoring to evaluate reflux, cross-sectional imaging when another cause must be excluded, or timed barium esophagram to assess emptying before and after treatment. For patients traveling internationally, organizing these tests efficiently is important. If reliable previous results are available, the medical team may review them before arrival; if not, testing can be planned as part of the evaluation.

Conditions and Indications Addressed by Achalasia Care

Achalasia care addresses the spectrum of esophageal motility disorders in which the lower esophageal sphincter fails to relax normally and swallowing becomes impaired. The classic indication is symptomatic primary achalasia confirmed by manometry, but the approach also includes careful evaluation of related or similar conditions that can influence treatment choice.

The main achalasia subtypes are type I, type II, and type III. Type I achalasia is characterized by minimal pressurization in the esophagus and absent normal peristalsis. Type II achalasia involves panesophageal pressurization and often responds well to therapies that relieve the lower sphincter obstruction. Type III achalasia is a spastic form, with abnormal contractions that may extend above the sphincter; it may require a longer myotomy and is often considered carefully when selecting POEM or surgical options.

Treatment may also be considered for patients with recurrent or persistent symptoms after prior therapy. Some patients have had previous dilation, botulinum toxin injection, or myotomy and later develop renewed difficulty swallowing. Re-treatment requires detailed assessment because scar tissue, reflux, esophageal shape, and prior procedural anatomy can affect both risk and expected benefit.

Advanced achalasia with a markedly enlarged or sigmoid-shaped esophagus may require special planning. In some patients, relieving the sphincter can still improve emptying and symptoms. In others, severe esophageal dilation or poor esophageal function may limit the expected improvement, and more complex surgical considerations may be discussed. The medical team’s role is to distinguish between achalasia that is likely to respond to sphincter-directed therapy and cases where alternative strategies may be needed.

A vital part of achalasia care is excluding pseudoachalasia, a condition in which symptoms and test findings resemble achalasia but are caused by another problem, such as a tumor at the gastroesophageal junction. This is one reason upper endoscopy, careful imaging when indicated, and expert review of symptoms such as rapid weight loss or short symptom duration are important. Treatment should not proceed until the diagnosis is sufficiently clear.

How Achalasia Treatment Is Performed

Achalasia treatment begins before the procedure itself. The first step is a structured consultation to review symptoms, prior testing, medical history, medications, allergies, nutritional status, and anesthetic risk. Patients are usually asked about the duration of dysphagia, whether symptoms involve solids, liquids, or both, the presence of regurgitation or aspiration, and any previous interventions. For international patients, records such as endoscopy reports, manometry tracings, barium swallow images, pathology results, and operative notes may be reviewed in advance whenever possible.

Preparation depends on the planned treatment. Because food and liquid can remain in the esophagus, patients may need a liquid diet for a period before the procedure and fasting instructions that are stricter than those used for routine endoscopy. In some cases, the esophagus is cleared during endoscopy before definitive treatment. Blood tests, electrocardiogram, chest imaging, anesthesia assessment, and medication adjustments may be required, especially for patients taking blood thinners or those with heart, lung, or metabolic conditions.

Pneumatic dilation is performed during upper endoscopy, usually with sedation or anesthesia. The physician places a balloon across the lower esophageal sphincter and inflates it in a controlled manner to stretch and partially disrupt the tight muscle. Imaging guidance may be used to confirm balloon position. The procedure itself is typically brief, but patients are monitored afterward for pain, bleeding, fever, or signs of perforation. Some treatment programs use graded dilation, meaning balloon size may be increased in stages depending on the response and safety considerations.

Botulinum toxin injection is also performed endoscopically. The physician injects small amounts of medication into the lower esophageal sphincter muscle to reduce its contraction. This option is less invasive and may be useful for frail patients, older patients with significant medical risk, or those who need temporary symptom control. Its effect often decreases over time, and repeated injections can sometimes make later definitive treatment more complex because of tissue changes.

Peroral endoscopic myotomy, or POEM, is an advanced endoscopic procedure performed under general anesthesia. The endoscopist enters the esophagus through the mouth, creates a small opening in the inner lining, and forms a tunnel within the esophageal wall. Through this tunnel, the tight muscle fibers of the lower esophageal sphincter, and in some cases part of the lower esophageal muscle above it, are carefully divided. The inner lining opening is then closed with endoscopic clips or another closure method. POEM allows the myotomy length to be tailored, which can be particularly relevant for spastic forms of achalasia.

Laparoscopic Heller myotomy is performed through small abdominal incisions under general anesthesia. The surgeon divides the tight muscle at the lower esophageal sphincter from the outside of the esophagus. It is commonly combined with a partial fundoplication, in which part of the stomach is wrapped around the lower esophagus to reduce the risk of reflux. This procedure has a long track record and remains an important option, especially when reflux control, anatomy, prior treatment, or surgeon assessment favors a laparoscopic approach.

The technologies used in achalasia care support both diagnostic accuracy and procedural precision. High-resolution manometry maps pressure patterns in the esophagus and helps classify the disease. Endoscopy allows direct visualization, biopsy if needed, and therapeutic access. Barium swallow imaging shows esophageal shape and emptying over time. During procedures, high-definition endoscopic visualization, imaging guidance, advanced closure tools, and minimally invasive surgical instruments may help physicians work with accuracy while limiting tissue trauma. Anesthesia monitoring supports patient safety during sedation or general anesthesia.

Procedure duration varies with the type of treatment, patient anatomy, prior interventions, and complexity. Botulinum toxin injection and dilation are generally shorter procedures. POEM and laparoscopic Heller myotomy take longer because they involve a controlled myotomy and careful closure or reconstruction. After treatment, patients are observed in a recovery area and may stay in the hospital depending on the procedure and clinical condition. Some patients require imaging or a swallow assessment before resuming oral intake.

Diet after treatment is gradual. Patients may begin with clear liquids, then advance to full liquids, soft foods, and eventually a broader diet as advised by the care team. Eating slowly, chewing thoroughly, taking small bites, and drinking fluids with meals may be recommended during the recovery period. Acid suppression medication may be prescribed, particularly after POEM or myotomy, because lowering the sphincter pressure can increase reflux risk. Follow-up is important to assess swallowing improvement, nutritional recovery, reflux symptoms, and any need for additional testing.

Why Acting Early Matters

Early evaluation and appropriate treatment can make a meaningful difference in achalasia. While symptoms may fluctuate, the underlying motility disorder usually persists. Delaying diagnosis may lead to progressive esophageal dilation, worsening food retention, nutritional decline, and greater risk of regurgitation into the airway. Patients may also undergo prolonged treatment for presumed reflux without addressing the true cause of dysphagia.

One concern with untreated achalasia is aspiration, especially at night. Food, saliva, or fluid retained in the esophagus can move upward and enter the airway, causing coughing, choking episodes, bronchitis, or pneumonia. Patients who wake with coughing, have recurrent chest infections, or need to sleep elevated should be assessed promptly.

Longstanding obstruction can also affect the structure and function of the esophagus. The esophagus may become enlarged, tortuous, or less effective as a reservoir. In advanced cases, symptom relief after treatment may be more limited because the esophageal body has lost much of its ability to empty, even when the sphincter is opened. Earlier treatment may help preserve function and prevent avoidable complications.

Another reason to act early is diagnostic safety. Symptoms that resemble achalasia can rarely be caused by malignancy or other structural disease. Rapidly progressive swallowing difficulty, significant weight loss, older age at symptom onset, or a short symptom history may prompt a more urgent evaluation. Confirming the correct diagnosis before treatment helps patients avoid delays in care for other serious conditions.

Potential Benefits of Achalasia Treatment

The expected benefits depend on the procedure, achalasia subtype, and individual health factors, but treatment is intended to reduce obstruction and improve daily function.

Benefit	What It Means for You
Improved swallowing	Food and liquids may pass into the stomach more easily, reducing the sensation of blockage or pressure during meals.
Less regurgitation	Reducing esophageal retention can decrease the return of undigested food or fluid, especially when lying down.
Better nutrition and weight stability	When eating becomes easier, patients may be able to broaden their diet and recover weight lost because of swallowing difficulty.
Reduced aspiration risk	Improved emptying may lower the chance of retained material moving into the airway, although ongoing precautions may be needed in advanced disease.
Improved quality of life	Meals may become less stressful, with greater confidence in social eating, travel, and daily routines.
More precise long-term planning	A confirmed diagnosis and documented treatment response help guide follow-up, reflux management, and decisions if symptoms recur.

Recovery Timeline After Achalasia Treatment

Recovery varies by treatment type, anesthesia, and individual healing, but many patients follow a staged return to eating and normal activity.

Time Period	What Patients Can Expect
Day 1	Patients are monitored after the procedure. Some may have chest or throat discomfort, mild abdominal bloating, or temporary nausea. Oral intake may be restricted until the team confirms it is safe to begin liquids.
First Week	Diet is usually limited to liquids and soft foods, depending on the procedure and physician instructions. Patients should eat slowly and report fever, severe pain, persistent vomiting, breathing difficulty, or worsening chest symptoms.
First Month	Many patients gradually expand their diet. Swallowing often improves, but adaptation can take time. Reflux symptoms may appear and should be discussed, as acid suppression or further testing may be needed.
Longer Term	Follow-up focuses on symptom control, nutrition, reflux monitoring, and whether additional treatment is needed. Some patients benefit from periodic endoscopy, pH testing, or repeat imaging based on symptoms and risk factors.

Factors That Influence Outcomes and a Good Result

A good result in achalasia care begins with an accurate diagnosis. High-resolution manometry is central because it distinguishes achalasia from other motility disorders and helps classify the subtype. Treatment success is generally strongest when the chosen procedure matches the motility pattern, esophageal anatomy, reflux risk, and patient’s overall condition. A patient with type III achalasia, for example, may require a different myotomy strategy than a patient with type II disease.

The duration and severity of disease also matter. Patients treated earlier, before the esophagus becomes markedly dilated or tortuous, may have more predictable improvement. In advanced achalasia, the lower sphincter may be successfully opened, but the esophageal body may still empty slowly. Expectations should be realistic and based on imaging, manometry, and clinical judgment.

Prior treatments can influence the next step. Botulinum toxin injection, repeated dilation, or previous myotomy may create scarring or alter anatomy. These factors do not necessarily prevent further care, but they can affect procedural planning and risk. Patients seeking a second opinion should provide previous endoscopy reports, manometry results, dilation details, operative notes, and any imaging to help the team understand what has been done.

Physician experience is important because achalasia procedures require technical skill and careful decision-making. POEM involves precise work within the esophageal wall. Pneumatic dilation must balance adequate sphincter disruption with the risk of perforation. Heller myotomy requires accurate muscle division and reflux prevention. A multidisciplinary setting allows complex cases to be discussed from more than one specialist perspective, which is especially valuable when symptoms recur or the diagnosis is uncertain.

Reflux management is another factor in long-term satisfaction. Any effective achalasia treatment that reduces lower sphincter pressure can increase the chance of gastroesophageal reflux. Some patients have typical symptoms such as heartburn or sour regurgitation, while others may have silent acid exposure detected only by testing. Follow-up care may include acid-reducing medication, lifestyle guidance, endoscopy, or pH monitoring. Reflux is not a reason to avoid appropriate achalasia treatment, but it should be anticipated and managed.

Patient participation also contributes to recovery. Following diet instructions, taking medications as prescribed, avoiding overly rapid diet advancement, attending follow-up appointments, and reporting warning signs early can support safer healing. After international travel, patients should have a clear plan for communication with the treating team and for local follow-up if needed.

Why International Patients Choose Acibadem for Achalasia Care

International patients often seek achalasia care at Acibadem because the condition requires more than a single procedure. It requires diagnostic confirmation, thoughtful selection among several treatment options, experienced procedural care, and structured follow-up. For patients traveling from the United States, Europe, the Middle East, or other regions, the ability to coordinate evaluation and treatment within an organized hospital system can be an important part of the decision.

Acibadem hospitals are JCI-accredited, reflecting internationally recognized standards for patient safety, clinical processes, and quality systems. In achalasia care, this matters in practical ways: anesthesia assessment, infection prevention, endoscopy safety, surgical protocols, imaging review, medication management, and discharge planning are all part of the patient experience. Complex patients may be evaluated through specialist boards or multidisciplinary discussions when the diagnosis, prior treatment history, or procedural choice requires broader input.

The care pathway is built around evidence-based international protocols. Patients may be evaluated by gastroenterology, advanced endoscopy, gastrointestinal surgery, radiology, anesthesiology, nutrition, and other specialties as appropriate. This collaborative model is particularly relevant for achalasia because the best treatment is individualized. Some patients may be better suited for POEM, while others may benefit from pneumatic dilation, laparoscopic Heller myotomy, botulinum toxin injection, or a staged approach. The recommendation is based on medical findings rather than a one-size-fits-all preference.

Modern diagnostic and therapeutic technologies support this process. High-resolution manometry helps define the motility disorder. Endoscopy evaluates the esophageal lining and allows certain treatments to be performed without external incisions. Barium imaging shows the functional passage of swallowed material and the shape of the esophagus. Minimally invasive surgical systems and advanced endoscopic instruments allow physicians to perform myotomy or dilation with controlled technique. These technologies are valuable because they help the team make decisions with greater clarity and perform procedures with attention to safety.

For international patients, medical coordination is also essential. Acibadem International provides support in more than 20 languages, helping patients with appointment scheduling, medical record transfer, translation support, hospital admission processes, and coordination of travel-related needs. This is especially important for a condition such as achalasia, where patients may arrive with incomplete testing or may require several steps before treatment. Clear communication helps reduce uncertainty and allows patients and families to understand the plan before, during, and after their hospital visit.

Personalized treatment planning is central to the experience. Before recommending a procedure, the team considers symptom severity, manometry subtype, esophageal diameter and shape, reflux history, prior interventions, age, general health, anesthesia risk, and personal goals. A younger patient with spastic achalasia, an older patient with multiple medical conditions, and a patient with recurrent dysphagia after prior surgery may each need a different strategy. The aim is to choose the safest effective option for that individual patient.

Patients also value continuity. Achalasia care does not end when swallowing improves after a procedure. Long-term management may include reflux surveillance, nutritional recovery, symptom scoring, medication adjustment, and reassessment if dysphagia returns. Acibadem’s international patient teams can help coordinate follow-up communication and share medical documentation so patients can continue care with their local physicians when they return home.

Taking the Next Step

If you have persistent difficulty swallowing, regurgitation of undigested food, unexplained weight loss, chest pressure with meals, or nighttime coughing, achalasia should be considered as part of a careful medical evaluation. If you have already been diagnosed, a second opinion can help clarify your achalasia subtype, compare treatment options, and determine whether dilation, POEM, botulinum toxin injection, or surgical myotomy is most appropriate for your situation.

The decision to travel for care is significant, particularly when eating has become difficult and daily life is affected. A thoughtful consultation can help you understand the likely diagnostic steps, the expected hospital stay, recovery instructions, reflux considerations, and follow-up plan. For many patients, the most reassuring first step is having their records reviewed by a team familiar with the full range of achalasia treatments.

To learn more, you may request a consultation or second opinion with Acibadem. Sharing your previous endoscopy, manometry, barium swallow, imaging, and treatment reports can help the medical team provide a more informed recommendation.

This information is general and is not a substitute for professional medical advice. Diagnosis and treatment decisions should be made after evaluation by a qualified physician.